Read the policies, reports, and plans on how we address issues like racism and reduce our carbon footprint, ensuring our actions align with the highest ethical standards.
In more than 70 countries, Médecins Sans Frontières provides medical humanitarian assistance to save lives and ease the suffering of people in crisis situations.
MSF Access pushes for access to, and the development of, life-saving and life-prolonging medicines, diagnostic tests and vaccines for people in our programmes and beyond.
Based in Paris, CRASH conducts and directs studies and analysis of MSF actions. They participate in internal training sessions and assessment missions in the field.
Based in Geneva, UREPH (or Research Unit) aims to improve the way MSF projects are implemented in the field and to participate in critical thinking on humanitarian and medical action.
Based in Brussels, MSF Analysis intends to stimulate reflection and debate on humanitarian topics organised around the themes of migration, refugees, aid access, health policy and the environment in which aid operates.
This logistical and supply centre in Brussels provides storage of and delivers medical equipment, logistics and drugs for international purchases for MSF missions.
This supply and logistics centre in Bordeaux, France, provides warehousing and delivery of medical equipment, logistics and drugs for international purchases for MSF missions.
This logistical centre in Amsterdam purchases, tests, and stores equipment including vehicles, communications material, power supplies, water-processing facilities and nutritional supplements.
BRAMU specialises in neglected tropical diseases, such as dengue and Chagas, and other infectious diseases. This medical unit is based in Rio de Janeiro, Brazil.
Our medical guidelines are based on scientific data collected from MSF’s experiences, the World Health Organization (WHO), other renowned international medical institutions, and medical and scientific journals.
Providing epidemiological expertise to underpin our operations, conducting research and training to support our goal of providing medical aid in areas where people are affected by conflict, epidemics, disasters, or excluded from health care.
Evaluation Units have been established in Vienna, Stockholm, and Paris, assessing the potential and limitations of medical humanitarian action, thereby enhancing the effectiveness of our medical humanitarian work.
MSF works with LGBTQI+ populations in many settings over the last 25-30 years. LGBTQI+ people face healthcare disparities with limited access to care and higher disease rates than the general population.
The Luxembourg Operational Research (LuxOR) unit coordinates field research projects and operational research training, and provides support for documentation activities and routine data collection.
The MSF Paediatric Days is an event for paediatric field staff, policy makers and academia to exchange ideas, align efforts, inspire and share frontline research to advance urgent paediatric issues of direct concern for the humanitarian field.
The MSF Foundation aims to create a fertile arena for logistics and medical knowledge-sharing to meet the needs of MSF and the humanitarian sector as a whole.
A collaborative, patients’ needs-driven, non-profit drug research and development organisation that is developing new treatments for neglected diseases, founded in 2003 by seven organisations from around the world.
Noma is a preventable and treatable neglected disease, but 90 per cent of people will die within the first two weeks of infection if they do not receive treatment.
The GeoMSF platform is a dynamic one-stop-shop website for all of MSF's GIS related services and products. Access maps and applications through the catalogue, request geographical support, or produce a map on GeoMSF.
A hidden health crisis, bites from venomous snakes make up to 2.7 million people sick each year. Up to nearly 140,000 people die, and a further 400,000 people can be left disfigured and/or disabled.
Despite having the highest mortality of all the 21 neglected tropical diseases recognised by the World Health Organization, investment in snakebite prevention and treatment remains severely underfunded and overlooked.
MSF teams treated around 7,000 people for snakebite in 2024. However, many patients arrive too late for treatment; timely access to polyvalent antivenom and empowered health services – such as having treatment and trained medical staff at health posts and clinics, rather than just hospitals – can save lives.
Understanding quickly which snake is responsible for a bite can also help improve antivenom treatment for patients. In collaboration with the University of Geneva, MSF teams have designed an artificial intelligence animal recognition software to help our colleagues who are not snake specialists distinguish venomous snakes from common snakes, and. The tool has been trained with more than 380,000 photos to recognise snake species.
video
Barriers to snakebite treatment
How barriers can be life-threatening for snakebite treatment
In Ethiopia's Amhara region, barriers to timely healthcare severely impact patients with life-threatening, time-sensitive neglected tropical diseases, such as snakebite.
Most of our patients’ testimonies highlight critical obstacles: insecurity along travel routes, transportation costs unaffordable to most, and initially using traditional medicines.
These delays can lead to preventable complications or deaths.
